| ID | 1136 |
| Name of the vaccine | Quadri Meningo |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Polysaccharide |
| Nucleic acid content | DNA |
| Age | Over 2 years |
| Description of the vaccine | Meningococcal polysaccharide vaccine (Group A, C, Y & W135) |
| Name of the manufacturer | Biomed Labs |
| Name of the manufacturing country | India |
| Year of manufacture | NA |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | NA |
| Vaccine formulation | Single dose vial with syringe |
| Dosage | Single dose (0.5 mL). |
| Mechanism of action | Elicits bactericidal antibody response. Immunity lasts for three years. |
| Route of administration | Subcutaneous |
| Indications | Hajj and Umrah pilgrims heading to Mecca, Saudi Arabia, travellers heading to disease prone areas, military recruits and children and adults exposed to infected patients. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For cerebrospinal meningitis |
| Side effects of vaccine | Pain ,redness ,transient hyperthermia , headache and vomiting. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | http://www.biomed.co.in/quadri-meningo/ |
| Other name | NA |
| Additional Links | NA
|